S. 3335 - Fair Accountability and Innovative Research Drug Pricing Act of 2016
- Sponsor:
- Tammy Baldwin
- Summary:
- A bill to require reporting regarding certain drug price increases, and for other purposes. (by CRS)
- Status:
- The bill has been referred to committee.
Fair Accountability and Innovative Research Drug Pricing Act of 2016
S. 3335 — 114th Congress (2015–2016)
- Summary
- A bill to require reporting regarding certain drug price increases, and for other purposes. (by CRS)
- Learn More
- At OpenCongress
- Title
- A bill to require reporting regarding certain drug price increases, and for other purposes.
- Other Titles
- Fair Accountability and Innovative Research Drug Pricing Act of 2016
- Fair Accountability and Innovative Research Drug Pricing Act of 2016
- Sponsor
- Tammy Baldwin
- Co-Sponsors
- Subjects
- Health
- Civil actions and liability
- Congressional oversight
- Consumer affairs
- Corporate finance and management
- Government information and archives
- Government studies and investigations
- Inflation and prices
- Medical research
- Prescription drugs
- Research and development
- Related Bills
- Major Actions
Introduced 9/15/2016 Referred to Committee - Bill History
-
There have been no votes on this bill.
Action Date Description Introduced 9/15/2016 9/15/2016 Introduced in Senate 9/15/2016 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. Number Sponsor Date Offered Status
- chart
- table
Total contributions given to Senators from Elderly issues/Social Security, which…
supported this bill
Elderly issues/Social Security | $224,126 |
$224,126 |
Contributions data source: OpenSecrets.org